
Follicular Neoplasm/Suspicious for a Follicular Neoplasm

5

Michael R. Henry, William H. Westra, Jeffrey F. Krane,
and Fernando Schmitt

Background

Prior to the introduction of the Bethesda System for Reporting Thyroid Cytopathology, there was great variability in the way thyroid aspirates that are suspicious for a follicular neoplasm were reported, as demonstrated by a review of the literature compiled for the National Cancer Institute (NCI)-sponsored Thyroid Fine-Needle Aspiration State of the Science Conference in 2007 [1]. The terminology used ranged from broad terms like “follicular lesion,” “follicular proliferation,” and “indeterminate” to the more specific terms like “rule out/suggestive of/suspicious for follicular neoplasm” or “follicular neoplasm” [2–10]. Much of this variability resulted from the fact that the so-called follicular lesions, comprised of nodular goiter (nodular hyperplasia), follicular adenoma, follicular variant of papillary carcinoma, follicular carcinoma, and the recently described noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), have overlapping cytomorphologic features and cannot be accurately distinguished by FNA alone. Nevertheless, certain cytologic features are very useful in raising the

M.R. Henry (✉)

Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA

e-mail: henry.michael@mayo.edu

W.H. Westra

Department of Pathology, The Johns Hopkins Hospital/The Johns Hopkins University School of Medicine, Baltimore, MD, USA

J.F. Krane

Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

F. Schmitt

Department of Pathology and Oncology, Medical Faculty of Porto University and IPATIMUP, Porto, Portugal

possibility of a neoplasm, most importantly the possibility of a carcinoma. In this regard, FNA can be considered a screening test, selecting for surgery those nodules with a greater probability of malignancy. The final diagnosis depends upon lobectomy because capsular and/or vascular invasion is the sine qua non of follicular carcinoma. In 2016 an international panel convened to review the 2007 terminology and criteria and proposed changes based on current knowledge [11]. The panel preferred having just one term for this category but recognized that, for practical purposes, the terms “follicular neoplasm” and “suspicious for a follicular neoplasm” are equally acceptable. A laboratory should choose the one it prefers and use it exclusively for that category. These synonymous terms should not be used separately to denote two distinct and different interpretations. “Suspicious for a follicular neoplasm (SFN)” is preferred over “follicular neoplasm (FN)” by some laboratories because a significant proportion (up to 35%) of cases that fulfill the criteria described herein prove not to be neoplasms but rather hyperplastic proliferations in nodular goiter [3–5, 12, 13]. The term SFN acknowledges this limitation, provides a rational framework for cytologic-histologic correlation, and preserves the credibility of cytopathologists with their clinical colleagues and the patients they serve. The goal of this category is to identify all potential follicular carcinomas and refer them for appropriate follow up, most often a diagnostic lobectomy [14]. It is not the goal of FNA to identify all follicular neoplasms, because adenomas are clinically innocuous, and there is little if any evidence to suggest progression from adenoma to carcinoma in the thyroid. Nevertheless, the terms FN and SFN are preferred over “suspicious for follicular carcinoma” for several reasons. Both FN and SFN have an established tradition in many laboratories; the terms recognize the impossibility of distinguishing adenoma from carcinoma by FNA; and both terms recognize that the majority of cases interpreted as FN/SFN turn out to be follicular adenomas simply because follicular adenomas outnumber follicular carcinomas in the population.

It is important to point out that cytologic-histologic correlation for the follicular-patterned thyroid nodules is hindered somewhat by the imperfect reproducibility among histopathologists in the diagnosis of nodular hyperplasia, follicular adenoma, follicular carcinoma, the follicular variant of papillary carcinoma, and the recently recognized noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) [15–17].

Definition

The general diagnostic category “follicular neoplasm” or “suspicious for a follicular neoplasm” refers to a cellular aspirate comprised of follicular cells, most of which are arranged in an altered architectural pattern characterized by significant cell crowding and/or microfollicle formation. The sample should be at least moderately cellular; sparsely cellular aspirates are excluded from this category and could be interpreted as *atypia of undetermined significance* or *follicular lesion of undetermined significance* (see Chap. 4). Cases that demonstrate suspicious or definitive nuclear features for papillary carcinoma are excluded from this category and should be classified as *suspicious*

for *malignancy* or *malignant*, respectively. Follicular-patterned aspirates with mild nuclear changes, such as increased nuclear size, nuclear contour irregularity, and/or chromatin clearing, can be classified as FN/SFN so long as true papillae and intranuclear pseudoinclusions are absent; a note that some nuclear features raise the possibility of an invasive follicular variant of papillary carcinoma or the more indolent noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) can be included [18, 19].

Criteria

Cytologic preparations are moderately or markedly cellular (Fig. 5.1a, b).

There is a significant alteration in follicular cell architecture, characterized by cell crowding, microfollicles, and dispersed isolated cells (Fig. 5.2a, b).

Follicular cells are normal-sized or enlarged and relatively uniform, with scant or moderate amounts of cytoplasm.

Nuclei are usually round and slightly hyperchromatic, with inconspicuous nucleoli (Fig. 5.2a, b).

Some nuclear atypia may be seen, either enlarged, variably sized nuclei, and prominent nucleoli (Fig. 5.3a, b) or enlarged nuclei with nuclear contour irregularity and mild and/or focal chromatin clearing.

Colloid is scant or absent.

Explanatory Notes

The hallmark of the FN/SFN specimen is the presence of a significant architectural alteration in the majority of the follicular cells. The altered architecture takes the form of crowded and overlapping follicular cells (Fig. 5.4a, b), some or most of which are arranged as microfollicles. To improve reproducibility, it has been




Fig. 5.1 Follicular neoplasm/suspicious for a follicular neoplasm. (a, b) Low magnification shows a highly cellular aspirate composed of uniform follicular cells arranged in crowded clusters and microfollicles (a smear, Diff-Quik stain; b smear, Papanicolaou stain).




Fig. 5.2 Follicular neoplasm/suspicious for a follicular neoplasm. (a) The crowded follicular cells have round nuclei of similar size and faint cytoplasm (smear, Diff-Quik stain). (b) Follicular cells are arranged as microfollicles and have round nuclei, evenly dispersed, granular chromatin, and small nucleoli (smear, Papanicolaou stain).




Fig. 5.3 Follicular neoplasm/suspicious for a follicular neoplasm. (a, b) Follicular cells in crowded, microfollicular arrangements show slight size variation, chromatin that is more “open” (less granular), and enlarged nucleoli (a smear, Papanicolaou stain; b ThinPrep, Papanicolaou stain).




Fig. 5.4 Follicular neoplasm/suspicious for a follicular neoplasm. (a, b) Microfollicles demonstrate nuclear overlap. Some are loosely cohesive clusters, and there are dispersed, isolated cells (a smear, Diff-Quik stain; b ThinPrep, Papanicolaou stain).




Fig. 5.5 Follicular neoplasm/suspicious for a follicular neoplasm. (a, b) Microfollicles may contain small amounts of colloid (a smear, Diff-Quik stain; b smear, Papanicolaou stain).

proposed that the “microfollicle” designation must be limited to crowded, flat groups of less than 15 follicular cells arranged in a circle that is at least two-thirds complete [15], but this recommendation has not been tested in a prospective study. A small amount of inspissated colloid may be present within the microfollicle (Fig. 5.5a, b). Microfollicles tend to be relatively uniform in size (“equisized”). In some cases, crowded follicular cells form ribbons of overlapping cells (“trabeculae”) that are more prominent than the microfollicles (Fig. 5.6).

It is important to recognize that rare macrofollicle fragments as well as some background colloid may be present in FN/SFN specimens. A small fragment of follicular cells is not necessarily a microfollicle: an important defining feature of the microfollicle is the crowding and overlapping of the follicular cells.

Cystic change is not common unless the neoplasm is large, at which point it may undergo central degenerative change with associated findings (foamy and hemosiderin-laden macrophages).

Although most FN/SFNs are highly cellular specimens, cellularity by itself is not sufficient to merit this designation [20]. If the majority of follicular cells are arranged in macrofollicle fragments (variably sized fragments without overlap or crowding), the sample can be considered benign. Similarly, nuclear atypia by itself is not diagnostic of malignancy or even neoplasia, as hyperplastic nodules and follicular adenomas can demonstrate nuclear enlargement and hyperchromasia [21–23].

An occasional dilemma is the sparsely cellular sample composed predominantly of microfollicles. Most cytologists are reluctant to make an FN/SFN interpretation on a sparsely cellular sample because of the discrepancy between the cellularity and the cell pattern. It is reasonable to interpret such cases as *atypia of undetermined significance* (or *follicular lesion of undetermined significance*) (see Chap. 4). In such cases, a repeat aspiration and/or molecular testing is a reasonable approach and is likely to resolve the discrepancy.

In some instances, both architectural features concerning for a follicular neoplasm and nuclear features concerning for papillary carcinoma are present.




Fig. 5.6 Follicular neoplasm/suspicious for a follicular neoplasm. In some cases, trabeculae of crowded follicular cells are more conspicuous than microfollicles (smear, Papanicolaou stain).

If the follicular cells show definitive nuclear features of papillary thyroid carcinoma, including frequent intranuclear pseudoinclusions, and if there are at least focal elements associated with classical papillary carcinoma (psammoma bodies and/or true papillae), the specimen should not be interpreted as FN/SFN but rather as “*malignant, papillary thyroid carcinoma*” [18, 24, 25]. If nuclear features of papillary carcinoma are not definitive or architectural features of classical papillary carcinoma are absent, such aspirates raise concern for invasive follicular variant of papillary carcinoma or NIFTP. Whether such aspirates are better classified as FN/SFN or “*suspicious for malignancy, suspicious for papillary thyroid carcinoma*” will be dictated by the quality and quantity of the cytologic changes. In either instance, an explanatory note regarding concern for NIFTP/invasive follicular variant of papillary carcinoma is warranted [17]. (See section “[Sample reports](#),” Example 4.) For lesions deemed borderline between FN/SFN and *suspicious for malignancy*, it may be more prudent to opt for the FN/SFN designation because the FN/SFN diagnosis is more likely to prompt a limited surgical approach (lobectomy).

Fine needle aspirations of parathyroid adenomas are composed of cells that resemble crowded and overlapping follicular cells (Fig. 5.7). Even when the FNA is performed with ultrasound guidance, it may not be clear to the aspirator that the lesion arises from a parathyroid gland rather than the thyroid, particularly for




Fig. 5.7 Follicular neoplasm/suspicious for a follicular neoplasm. These crowded, uniform cells are arranged in thick trabeculae mimicking neoplastic follicular cells. Lobectomy revealed an unsuspected parathyroid adenoma (smear, hematoxylin, and eosin stain).

parathyroid glands located within the thyroid parenchyma or thyroid capsule. When submitted as a “thyroid FNA” specimen, parathyroid adenomas are often misinterpreted as FN/SFN. If there is a clinical suspicion that the lesion may be parathyroid, or if there are cellular features suggesting that possibility (e.g., crowded trabeculae in an aspirate lacking colloid), then the possibility of a parathyroid lesion might be suggested in the report [26]. (See section “[Sample reports](#),” Example 5.) The gene expression classifier Afirma (Veracyte, Inc.), which can be used as an adjunct to cytology for FN/SFN cases, includes a cassette that recognizes the gene expression profile of parathyroid neoplasms [27, 28].

There are robust data on the predictive value of the FN/SFN interpretation because most patients with this FNA result undergo surgery [3, 4, 9, 12]. The likelihood that the nodule is neoplastic is 65–85%. The rate of malignancy is significantly lower, at 25–40% (see Table 1.2, [Chap. 1](#)). Moreover, not all the malignancies prove to be follicular carcinomas: many if not most of the malignancies (27–68%) are interpreted histologically as papillary thyroid carcinoma [3, 4, 9, 12]. There are a number of explanations for this discrepancy. Some tumors, particularly the follicular variant of papillary carcinoma and NIFTP, may have cellular features of papillary carcinoma that are not fully developed throughout the entire nodule and thus may not be appreciated in the FNA sample. In other cases, however, the discrepancy may be due to the imperfect reproducibility of the histologic diagnoses of follicular carcinoma and follicular variant of papillary carcinoma [15].

Management

According to the 2015 American Thyroid Association management guidelines, diagnostic surgical excision (lobectomy) is the long-established standard of care for this diagnosis [14]. After consideration of clinical and sonographic features, however, molecular testing may be used to supplement malignancy risk assessment data in lieu of proceeding directly with surgery [14, 29, 30].

Sample Reports

If an aspirate is interpreted as FN/SFN, it is implied that the sample is adequate for evaluation. (An explicit statement of adequacy is optional.) The general category FN/SFN is a self-sufficient interpretation; narrative comments that follow are optional. An educational note specifying the risk of malignancy for this interpretation, derived from the laboratory itself or from the literature, is optional.

Example 1

SUSPICIOUS FOR A FOLLICULAR NEOPLASM.

Example 2

FOLLICULAR NEOPLASM.

Example 3

SUSPICIOUS FOR A FOLLICULAR NEOPLASM.

Cellular aspirate of follicular cells with a predominantly microfollicular architecture, scattered isolated cells, and scant colloid.

Example 4

SUSPICIOUS FOR FOLLICULAR NEOPLASM (*SEE NOTE*).

Note: Although the architectural features suggest a follicular neoplasm, some nuclear features raise the possibility of an invasive follicular variant of papillary carcinoma or its recently described indolent counterpart, NIFTP; definitive distinction among these entities is not possible on cytologic material.

Example 5

SUSPICIOUS FOR A FOLLICULAR NEOPLASM.

Cellular aspirate composed predominantly of crowded uniform cells without colloid. The features suggest a follicular neoplasm, but the possibility of a parathyroid lesion cannot be excluded. Correlation with clinical, serologic, radiologic, and molecular test findings (if any) should be considered.

References

1. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. *Diagn Cytopathol.* 2008;36(6):425–37.
2. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. *Ann Intern Med.* 1993;118:282–9.
3. Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. *Cancer.* 2007;111(5):306–15.
4. Deveci MS, Deveci G, LiVolsi VA, Baloch ZW. Fine-needle aspiration of follicular lesions of the thyroid diagnosis and follow-up. *Cytojournal.* 2006;3:9.
5. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of “follicular neoplasm”: a gray zone in thyroid fine-needle aspiration cytology. *Diagn Cytopathol.* 2002;26(1):41–4.
6. Yang GC, Liebeskind D, Messina AV. Should cytopathologists stop reporting follicular neoplasms on fine-needle aspiration of the thyroid? *Cancer.* 2003;99(2):69–74.
7. Greaves TS, Olvera M, Florentine BD, et al. Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. *Cancer.* 2000;90(6):335–41.
8. Guidelines of the Papanicolaou Society of Cytopathology for the examination of fine-needle aspiration specimens from thyroid nodules. The Papanicolaou Society of Cytopathology Task Force on Standards of Practice. *Diagn Cytopathol.* 1996;15(1):84–9.
9. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. *Cancer.* 2007;111(6):508–16.
10. Wang HH. Reporting thyroid fine-needle aspiration: literature review and a proposal. *Diagn Cytopathol.* 2006;34(1):67–76.
11. Pusztaszeri M, Rossi ED, Auger M, Baloch Z, Bishop J, Bongiovanni M, Chandra A, Cochand-Priollet B, Fadda G, Hirokawa M, Hong SW, Kakudo K, Krane JF, Nayar R, Parangi S, Schmitt F, Faquin WC. The Bethesda System for reporting thyroid cytopathology: proposed modifications and updates for the second edition from an international panel. *Acta Cytol.* 2016;60:399–405.
12. Schlinkert RT, van Heerden JA, Goellner JR, et al. Factors that predict malignant thyroid lesions when fine-needle aspiration is “suspicious for follicular neoplasm”. *Mayo Clin Proc.* 1997;72(10):913–6.
13. Kelman AS, Rathan A, Leibowitz J, Burstein DE, Haber RS. Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens. *Thyroid.* 2001;11(3):271–7.
14. Haugen BR, Alexander E, Bible KC, et al. American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. *Thyroid.* 2016;26(1):1–133.
15. Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. *Am J Clin Pathol.* 2008;130(5):736–44.
16. Baloch ZW, Seethala RR, Faquin WC, Papotti MG, Basolo F, Fadda G, Randolph GW, Hodak SP, Nikiforov YE, Mandel SJ. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): a changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology. *Cancer Cytopathol.* 2016;20
17. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. *JAMA Oncol.* 2016; 1;2(8):1023–1029.
18. Krane JF, Alexander EK, Cibas ES, Barletta JA. Coming to terms with NIFTP: a provisional approach for cytologists. *Cancer Cytopathol.* 2016; doi:[10.1002/cncy.21769](https://doi.org/10.1002/cncy.21769).
19. Maletta F, Massa F, Torregrossa L, Duregon E, Casadei GP, Basolo F, Tallini G, Volante M, Nikiforov YE, Papotti M. Cytological features of “non-invasive follicular thyroid neoplasm

- with papillary-like nuclear features” and their correlation with tumor histology. *Hum Pathol.* 2016;54:134–42.
20. Renshaw AA, Wang E, Wilbur D, Hughes JH, Haja J, Henry MR. Interobserver agreement on microfollicles in thyroid fine-needle aspirates. *Arch Pathol Lab Med.* 2006;130(2):148–52.
 21. Suen KC. How does one separate cellular follicular lesions of the thyroid by fine-needle aspiration biopsy? *Diagn Cytopathol.* 1988;4:78–81.
 22. Stelow EB, Bardales RH, Crary GS, et al. Interobserver variability in thyroid fine-needle aspiration interpretation of lesions showing predominantly colloid and follicular groups. *Am J Clin Pathol.* 2005;124(2):239–44.
 23. Clary KM, Condel JL, Liu Y, Johnson DR, Grzybicki DM, Raab SS. Interobserver variability in the fine needle aspiration biopsy diagnosis of follicular lesions of the thyroid gland. *Acta Cytol.* 2005;49(4):378–82.
 24. Howitt BE, Chang S, Eszlinger M, Paschke R, Drage MG, Krane JF, Barletta JA. Fine needle aspiration diagnoses of non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma. *Am J Clin Pathol.* 2015;144:850–7.
 25. Strickland KC, Vivero M, Jo VY, Lowe A, Hollowell M, Qian X, Wieczorek T, French CA, Teot LA, Sadow PM, Alexander EK, Cibas ES, Barletta JA, Krane JF. Pre-operative cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): a prospective analysis. *Thyroid.* 2016;26(10):1466–71.
 26. Agarwal AM, Bentz JS, Hungerford R, Abraham D. Parathyroid fine-needle aspiration cytology in the evaluation of parathyroid adenoma: cytologic findings from 53 patients. *Diagn Cytopathol.* 2009;37(6):407–10.
 27. Kloos RT. Molecular profiling of thyroid nodules: current role for the Afirma gene expression classifier on clinical decision making. *Mol Imaging Radionucl Ther.* 2017;26(Suppl 1):36–49.
 28. Domingo RP, Ogden LL, Been LC, Kennedy GC, Traweek ST. Identification of parathyroid tissue in thyroid fine-needle aspiration: a combined approach using cytology, immunohistochemical and molecular methods. *Diagn Cytopathol* (in press).
 29. Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with molecular tests guide extent of thyroid surgery 767 follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. *Cancer.* 2014;120(23):3627–34.
 30. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR. Diagnosis of benign thyroid nodules with indeterminate FNA cytology. *N Engl J Med.* 2012;367(8):705–15.